Navigation Links
Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target

OSS, the Netherlands, June 27, 2007-Organon, the human healthcare business unit of Akzo Nobel, announced today that two out of three Phase III clinical trials with corifollitropin alfa (Org 36286), a new long-acting fertility hormone, have reached their randomization target.

Corifollitropin alfa is a new recombinant fertility hormone. It is the first of a new class of gonadotropins (a sustained follicular stimulant or SFS) of which, due to its long half-life, one single injection may replace the first 7 injections with conventional gonadotropins during a fertility treatment cycle.

The objective of the ENGAGE trial, the largest double-blind fertility trial ever performed, is to demonstrate clinical efficacy and safety of corifollitropin alfa 150 µg in a double-blind comparison with Organon’s Puregon®, one of the most commonly used preparations to treat infertile patients. The recruitment goal of the ENGAGE trial was to include a total of 1400 patients from 34 fertility clinics in Europe, USA and Canada and was started in July, 2006. The study reached its randomization target on June 10, 2007.

A second trial, the ENSURE trial, is an efficacy and safety trial with corifollitropin alfa 100 µg designed specifically for women who weigh less than 60 kg (133 lbs). This double-blind study comparing corifollitropin alfa with Puregon® was started in January 2007 in 19 clinical trial centers in Europe and Asia with a recruitment goal of 330 patients by June 30, 2007. All 330 subjects have now been randomized.

David Nicholson, executive vice-president Research and Development at Organon commented: “The enthusiasm and dedication of investigators and staff involved in these trials was decisive in reaching our recruitment targets.”

A third Phase III trial in the LIFE program (the TRUST trial) focuses on safety of repeated treatments with corifollit
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:11/26/2014)... YORK and LONDON , ... of market intelligence, MarketResearch.com is pleased to announce the ... and Consultancy focusing on the active pharmaceutical ingredient (API) ... visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . In IQ4I,s ... – Forecast to 2020 , IQ4I ...
(Date:11/26/2014)... Reinforcing its commitment to enabling confident diagnosis ... PHG AEX: PHIA) today announced 510(k) clearance from ... IQon Spectral CT , presenting an entirely new ... a new dimension to Computed Tomography (CT) imaging, delivering ... based on their material content within a single scan. ...
(Date:11/26/2014)... 25, 2014  Unilife Corporation (NASDAQ: UNIS, ASX: UNS), ... systems, today announced that its Chairman and CEO, ... Piper Jaffray 26th Annual Healthcare Conference at the New ... December 2, 2014. The conference presentation ... listen only Webcast. To listen, please go to: ...
Breaking Medicine Technology:MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2
... 27, 2011   FHSSA counts its partnership initiative ... known as the Foundation for Hospices in Sub-Saharan ... between US hospice programs and organizations providing care ... assistance, support and friendship.  They are working collaboratively ...
... /PRNewswire-Asia/ -- On October 18, 2011, the "TICH- BIOTRONIC ... by TEDA International Cardiovascular Hospital (hereinafter referred to as ... Co. KG of Germany. This center is the first ... for the online monitoring of the conditions of patients ...
Cached Medicine Technology:FHSSA Launches New Campaign to Partner US Hospices with Programs in Sub-Saharan Africa 2"TICH- BIOTRONIC Pacemaker Wireless Monitoring Services Centre" Founded 2"TICH- BIOTRONIC Pacemaker Wireless Monitoring Services Centre" Founded 3
(Date:11/28/2014)... Dr. Andrew Campbell, one of the ... expansion of Quintessa Aesthetic Center into a third location ... W307 N1497 Golf Road in Suite 200 and will ... the new Delafield location will offer a variety of ... Botox, filler injectables , micro laser peels, chemical ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Dr. Paul Vitenas, one ... hold a Glitter & Glow Holiday Event for those in the ... offered at his practice. Glitter & Glow will take place on ... Vitenas’ new location in the heart of Houston at 4208 Richmond ... holidays and hope that you will come and celebrate the season ...
(Date:11/28/2014)... Written and narrated by award winning author Dr. ... “The Happiest Man In the World: Life Lessons From a ... why Project C.U.R.E. came to be. , Raised in the ... Reverend Richard W. Jackson, Dr. Jackson exceeded his goal of ... that he wasn’t happy. Prompted by this realization, James and ...
(Date:11/28/2014)... Alex Kramer HealthDay Reporter ... involved in the kitchen, through cooking classes or at home, ... to a recent review. Cooking programs and classes for ... according to the new research. And, although the review didn,t ... that such programs might help children develop long-lasting healthy habits. ...
(Date:11/28/2014)... 2014 An inventor and dental assistant from ... patient’s filling and it was almost impossible to reach. "This ... she said. , The patent-pending Access Light allows for easier ... areas of the mouth, as well as avoids harm to ... Easy to use and clean, it also helps prevent cross-contamination. ...
Breaking Medicine News(10 mins):Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2Health News:Want Kids to Eat Better? Get Them Cooking 2Health News:Want Kids to Eat Better? Get Them Cooking 3
... case of the disease fears of the deadly SARS virus ... cleared a woman suspected of being India's first SARS case. ... a hospital after he arrived from Australia via Singapore. He ... those of the deadly SARS virus.// ,Airport authorities in ...
... at St Mary's Hospital, Manchester, UK, has shown that family history ... with breast cancer. A survey of a group of 99 women ... a third of them had a strong history of either breast ... of cancer, 44 per cent were found to carry// mutations in ...
... Pennsylvania School of Medicine in,Philadelphia, USA, has shown that people ... ability much similar to those who go without sleep for ... the March issue of the,journal Sleep involved 48 participants divided ... for two weeks, the second group slept six hours a ...
... new study by researchers at the Institute of Neurology, ... migraine attack. The researchers who,studied 97 people with migraine ... into the condition and also help manage it better.// ... hand-held electronic diary to record,symptoms of the attack on ...
... help improve patient safety by reducing medication errors. Medication errors ... 7,000 deaths. These errors have been attributed to problems of ... or too many new drugs for doctors to remember as ... between 45,000 and 98,000 death due to medical mistakes. The ...
... called juvenile macular degeneration, is an inherited disease which ... from a defect in the ABCR gene, which is ... a vision byproduct, from retinal rods and cones. Rods ... layer of cells near the retina. The accumulation of ...
Cached Medicine News:
Meyerding Laminectomy Retractors, self-retaining....
Scoville-Haverfield Hemilaminectomy Retractor...
Bookwalter Spinal Retractor...
Circular Spine Retractor System for microsurgical interventions in the lumbar and cervical spine region....
Medicine Products: